Zum Inhalt springen

Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts — October 01, 2026

01.10.2026 · 10 Min.

Shownotes

Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.

In this episode
  1. CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment — Skinnyvip

    CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment # CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment Dr. SkinnyVIP September 15, 2026 ~9 min read Formulary details current as of September 15, 2026 This guide summarizes CVS Caremark’s May 28, 2026 announcement and standard commercial formulary template as of the…

  2. Critics say GLP-1 coverage shift raises equity issues — The Boston Globe

    # Critics say GLP-1 coverage shift raises equity issues Author: Alison Kuznitz Published: 2026-09-30T21:56:03.616000+00:00 Source: bostonglobe.com (bostonglobe.com) Language: en ## Story Critics say GLP-1 coverage shift raises equity issues # Critics say GLP-1 coverage shift raises equity issues A woman holds a Wegovy injector pen in her Wenatchee, Wash., home, on June 3, 2024. M. SCOTT…

  3. Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version — Drugtopics

    # Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version Published: 2026-09-30T14:00:00+00:00 Source: drugtopics.com (drugtopics.com) Language: en ## Story --- ## title: "Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version" description: "Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled…

  4. Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — EurekAlert!

    Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study # Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study By PR Newswire | September 30, 2026,…

  5. Newsom signs law allowing California-made GLP-1 drugs — Redding

    Newsom signs law allowing California-made GLP-1 drugs # California’s GLP-1 law could expand access to obesity treatment Ernesto Centeno Araujo USA TODAY NETWORK Sept. 29, 2026, 4:42 p.m. PT Gov. Gavin Newsom recently signed a law that would allow California to make and distribute a generic version of a popular class of weight-loss drugs through the state's CalRx program. California…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Alle Folgen von GLP-1 Daily: Ozempic & Wegovy News

Einstellungen

Darstellung

Sprache

Bestimmt, welche Sender dir auf der Startseite zuerst gezeigt werden.

Verlauf

Zuletzt gehörte Sender und Folgen und deine letzten Suchen liegen nur in diesem Browser.

Hinweise

Ein kurzer Hinweis, wenn ein Podcast, dem du folgst, eine neue Folge hat. Einzelne Podcasts stellst du über die Glocke auf ihrer Seite ab.

Konto

Favoriten speichern – in der App und auf der Website.

Tastenkürzel

/
Suche öffnen
Leertaste
Abspielen oder anhalten
← →
Im Player: 15 s zurück, 30 s vor (Folgen) · im Regal: nächste Kachel
↑ ↓
Im Regal: Ziel innerhalb der Kachel
Pos1 / Ende
Im Regal: erste bzw. letzte Kachel
Esc
Fenster oder Menü schließen
?
Diese Übersicht
Läuft gerade

Zur Senderseite

Als Nächstes

    Folgen mit „Als Nächstes“ vormerken – sie laufen nach der aktuellen Folge.